🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 20 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
26/10/2021 36,44 37,03 35,72 35,79 -1,13% 3,59% 373.900
25/10/2021 36,03 36,48 35,40 36,20 +0,58% 3,00% 313.300
22/10/2021 36,06 36,23 35,41 35,99 +0,03% 2,27% 397.400
21/10/2021 35,93 36,37 35,70 35,98 +0,31% 1,88% 400.700
20/10/2021 36,30 36,83 35,40 35,87 -1,10% 3,94% 601.300
19/10/2021 37,59 37,89 36,21 36,27 -2,94% 4,47% 524.700
18/10/2021 36,30 37,43 35,69 37,37 -1,89% 4,79% 1.216.700
15/10/2021 37,82 38,25 37,19 38,09 +2,42% 2,80% 450.800
14/10/2021 37,60 38,68 37,05 37,19 +0,03% 4,35% 429.900
13/10/2021 36,72 37,19 35,92 37,18 +1,09% 3,46% 289.100
12/10/2021 37,14 37,33 36,11 36,78 -0,92% 3,28% 301.700
11/10/2021 36,48 37,54 36,46 37,12 +1,06% 2,97% 168.200
08/10/2021 36,72 37,44 35,85 36,73 -0,19% 4,33% 309.100
07/10/2021 36,25 37,49 36,25 36,80 +1,66% 3,42% 231.600
06/10/2021 36,17 36,53 35,77 36,20 -0,88% 2,10% 517.200
05/10/2021 36,76 37,74 35,93 36,52 -0,90% 4,92% 364.400
04/10/2021 37,53 38,04 36,37 36,85 -2,33% 4,45% 332.700
01/10/2021 37,17 37,82 36,30 37,73 +1,40% 4,09% 494.100
30/09/2021 37,07 38,38 37,00 37,21 +0,43% 3,72% 417.500
29/09/2021 38,47 39,13 36,92 37,05 -3,26% 5,74% 362.900
28/09/2021 38,88 39,75 37,97 38,30 -1,59% 4,58% 1.075.100
27/09/2021 39,04 39,71 38,67 38,92 -0,94% 2,66% 660.200
24/09/2021 39,42 39,95 38,69 39,29 -0,48% 3,19% 734.100
23/09/2021 42,10 42,10 37,97 39,48 -9,90% 9,81% 1.334.500
22/09/2021 43,64 44,23 43,31 43,82 +0,57% 2,11% 398.600
21/09/2021 41,70 43,90 41,60 43,57 +4,76% 5,52% 395.300
20/09/2021 41,84 42,77 41,40 41,59 -2,44% 3,27% 353.300
17/09/2021 40,96 42,78 40,21 42,63 +5,03% 6,27% 1.049.200
16/09/2021 40,69 40,98 39,48 40,59 +0,07% 3,69% 287.700
15/09/2021 40,92 41,17 40,32 40,56 -1,05% 2,08% 511.500